네뷸라이저 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Nebulizer Market Growth & Trends:

The global nebulizer market size is estimated to reach USD 1.77 billion by 2030, registering a CAGR of 6.35% from 2025 to 2030, according to a new report by Grand View Research, Inc., Rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices, and rising geriatric population worldwide are the major factors leading to the market growth.

The COVID-19 outbreak has affected millions of people around the globe. Asthma or COPD patients, who were aware regarding the risk of airborne transmission of COVID-19, were hesitant with regard to the use of inhaled medications, which are considered as a potential source of viral transmission and immunosuppression. Though, medical practitioners advised all such patients to continue using their prescribed inhaled medications, including nebulizers. Nebulized albuterol was recommended in some parts of the U.S. as an alternative to albuterol rescue inhalers when pharmacies faced shortage of albuterol inhalers.

COVID-19 affects many elderly people. According to the American Lung Association (ALA) in 2020, nebulized therapy is a safe and effective way to manage COPD at home for patients during COVID-19. Consequently, promotes the nebulizers demand.

According to the Population Reference Bureau report, "Aging in the United States", the geriatric population in U.S. is estimated to increase from 48 million in 2016 to 98 million by 2060. Elderly people are susceptible to respiratory diseases such as COPD and sleep apnea. Therefore, growing geriatric population is expected to expand the patient pool for manufacturers and propel the growth of the market.

Increasing commercial acceptance of mesh nebulizers due to accurate delivery of drug to the lung and lower residual volumes also aids in market growth. Furthermore, Technological advancements such as drug-device combination is further expected to create newer opportunity in the nebulizer market.

On the other hand, drug loss during nebulization is the major factor restraining the market growth. However, this can also act as an opportunity for the mesh nebulizer manufacturers as the devices are manufactured to deliver accurate drug dosage while reduce drug loss.

Nebulizer Market Report Highlights:

• By type, the jet nebulizers segment held the largest revenue share of 64.82% in 2024, owing to the low cost of the devices.
• Mesh nebulizers type segment is expected to witness lucrative CAGR over the forecast period, due to the technologically advanced compact size devices and minimized drug loss.
• Based on application, the chronic obstructive pulmonary disorder (COPD) segment accounted for the largest market share in 2024, owing to the high global prevalence of COPD, recent technological advancements have made nebulizers more portable and user-friendly.
• In 2024, the hospitals segment accounted for the largest revenue share of 67.25% in 2024, owing to the favorable reimbursement policies and significant patient footfall.
• North America held the largest revenue share of 34.06% in 2024. Respiratory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and bronchitis have become more prevalent, thereby contributing to market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Nebulizers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic respiratory diseases
    • 3.2.1.2. Growing demand for home healthcare products
    • 3.2.1.3. Increasing availability of advanced and cost-effective technologies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Drug loss during drug delivery
    • 3.2.2.2. Risk of disease transmission
    • 3.2.2.3. Stringent regulatory requirements
• 3.3. Nebulizers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Emerging Technology Trends
  • 3.3.5. COVID-19 Impact Analysis

Chapter 4. Nebulizers Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Nebulizers Market Type Movement Analysis
• 4.3. Global Nebulizers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Jet Nebulizer
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Mesh Nebulizer
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Active Mesh Nebulizer
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Passive Mesh Nebulizer
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Ultrasonic Nebulizer
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Nebulizers Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Nebulizers Market Application Movement Analysis
• 5.3. Global Nebulizers Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. COPD
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cystic Fibrosis
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Asthma
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. ebulizers Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Nebulizers Market End Use Movement Analysis
• 6.3. Global Nebulizers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospital and Clinics
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Emergency Centers
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Home Healthcare
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Nebulizers Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share/Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. OMRON Corporation
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. GE Healthcare
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Koninklijke Philips N.V.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Vectura Group Plc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. PARI Respiratory Equipment, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Aerogen
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. DeVilbiss Healthcare LLC
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Beurer GmBH
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Microlife Corporation
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. GF Health Products, Inc.,
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Rossmax International Ltd.
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. BESCO MEDICAL LIMITED
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Bremed Ltd.
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives